BeyondSpring Inc (BYSI)vsMerck & Company Inc (MRK)
BYSI
BeyondSpring Inc
$1.55
+1.96%
HEALTHCARE · Cap: $60.45M
MRK
Merck & Company Inc
$109.18
+2.73%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 3465305% more annual revenue ($65.01B vs $1.88M). MRK leads profitability with a 28.1% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 59/100 (C).
BYSI
Avoid20
out of 100
Grade: F
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+87.2%
Fair Value
$11.09
Current Price
$1.55
$9.54 discount
Margin of Safety
-16.2%
Fair Value
$96.56
Current Price
$109.18
$12.62 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : BYSI
Revenue growth of 14.3% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : BYSI
The primary concerns for BYSI are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
BYSI carries more volatility with a beta of 0.51 — expect wider price swings.
BYSI is growing revenue faster at 14.3% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (59/100 vs 20/100), backed by strong 28.1% margins. BYSI offers better value entry with a 87.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeyondSpring Inc
HEALTHCARE · BIOTECHNOLOGY · USA
BeyondSpring Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in New York, New York.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?